ACS Publications. Most Trusted. Most Cited. Most Read
The Antibacterial Research and Development Pipeline Needs Urgent Solutions
More

OR SEARCH CITATIONS

My Activity
Publications

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:ACS Infect. Dis. 2020, 6, 6, 1289-1291
  • Free to Read
Viewpoint

The Antibacterial Research and Development Pipeline Needs Urgent Solutions
Click to copy article linkArticle link copied!

Open PDF

ACS Infectious Diseases

Cite this: ACS Infect. Dis. 2020, 6, 6, 1289–1291
Click to copy citationCitation copied!
https://doi.org/10.1021/acsinfecdis.0c00044
Published June 12, 2020

Copyright © 2020 American Chemical Society. This publication is available under these Terms of Use.

Request reuse permissions

Abstract

Click to copy section linkSection link copied!

Despite ongoing efforts to stimulate investment and research into the development of new antibiotics, the clinical pipeline remains insufficient, in particular to treat critical resistant Gram-negative bacterial infections. The two new reports released by the World Health Organization on the preclinical and clinical antibacterial pipeline show that the current clinical pipeline is very dry and dominated by derivatives of existing classes. There are only 32 antibacterials in the clinical pipeline that target the WHO priority pathogens, of which only 6 fulfill at least 1 of the innovation criteria as defined by the WHO. Further upstream, the preclinical pipeline review identified 252 antibacterial agents in preclinical development of which over one third are nontraditioanl products which highlights the degree of innovation in the preclinical pipeline. The pipeline is also heavily reliant on small- or medium-sized enterprises, which is unsustainable in the long run, and more investment, more players, and a rethinking of the market dynamics is needed. It is encouraging that the pharmaceutical industry, governments, and other concerned stakeholders are currently discussing new ideas.

This publication is licensed for personal use by The American Chemical Society.

Copyright © 2020 American Chemical Society

Subjects

what are subjects

SPECIAL ISSUE

This article is part of the Antibiotics special issue.

Fighting antimicrobial resistance requires concerted action on many fronts. (1) The most cost-effective measures are without a doubt investments in better infection prevention and control in hospitals that will minimize hospital-acquired infections and, in parallel, improve the way existing antibiotics are used in hospitals and in the community to delay the inevitable rise of resistance levels. However, even if globally we were to achieve success on this front (and for the time being we are not), then we will also need new antibiotics in the long run to replace those that are becoming increasingly ineffective. The need for increased investment in research and development of new antibacterial treatments has been high on the agendas of the G7, the G20, and many other international fora. (2,3) This has translated into various new initiatives that are starting to show impact populating the clinical and preclinical antibacterial pipelines. The latter can be seen in the review of the preclinical antibacterial pipeline that was published by WHO in January 2020. (4) The report and the respective WHO online database capture 252 antibacterial agents being developed by 145 individual institutions against the 12 antibiotic-resistance bacteria on the WHO priority pathogens list, Mycobacterium tuberculosis and Clostridioides difficile. From the review, the preclinical antibacterial pipeline seems to be dynamic and scientifically diverse, including research projects from institutions with a wide geographical distribution. Over one-third of the projects are focused on nontraditional products, including many projects on phages and phage-derived products, antivirulence agents, immunomodulators, and microbiome-modifying therapies and potentiators, among others. This is in part due to new funding mechanisms, in particular, BARDA, CARB-X and NOVO REPAIR. However, let us not be overly enthusiastic. We estimate that the publicly available WHO database of the preclinical pipeline reflects more than 80% of the complete preclinical pipeline. (5) (The data at the product level is available and downloadable on the WHO Global Observatory on Health R&D: https://www.who.int/research-observatory/monitoring/processes/antibacterial_products_preclinical/en). Two hundred fifty-two projects may seem high, but the fact that the preclinical pipeline to a large extent consists of nontraditional products for which the regulatory pathway is not yet well established indicates that failure rates are likely to be even higher than average, meaning that at best only a handful of these projects will ever make it to market.

Looking at the clinical antibacterial pipeline is not very encouraging either: the third WHO annual pipeline analysis published in January 2020 contains 50 antibiotics and combinations (with a new therapeutic entity) and 10 biologicals in clinical phases 1 to 3 (Scheme 1). (6)

Scheme 1

Scheme 1. Clinical Antibacterial Pipeline
High Resolution Image
Download MS PowerPoint Slide
Of these, 32 antibiotics are active against the WHO priority pathogens. The pipeline also includes 12 agents targeting tuberculosis and 6 targeting C. difficile infections. Of the 10 biological treatments in clinical development, 6 target S. aureus, 2 target P. aeruginosa, and 2 target C. difficile.

The 10 biological treatments (6 monoclonal antibodies, 2 polyclonal antibodies, and 2 phage-derived endolysins) are all developed as preemptive or adjunctive treatments, so while adding to the portfolio of options, they will be administered on top of traditional antibiotics or used to depopulate patients to prevent further dissemination and infections. They are thus unlikely to replace therapeutic antibiotics. It also remains to be seen what the clinical uptake of these agents will be.

The reality is that both the preclinical and the clinical antibacterial pipelines are driven by small- or medium-sized enterprises (SMEs). Major pharmaceutical companies are continuing to exit the field, and the AMR Industry Alliance reports that private investment is likely to continue to decline from an already very low level. (7) This is only partially compensated for by the funding provided by BARDA and GARDP, a foundation that was set up by WHO and the Drugs for Neglected Diseases initiative (DNDi) to develop new missing antibacterial treatments, the NOVO REPAIR Impact Fund, and other public funding initiatives.

A comparison of the antibacterial pipeline to the more than 5700 clinical development projects targeting different forms of cancer (8) shows clearly that the 60 products constitute a very limited pipeline, particularly considering the average success rate of about 14%. However, it is even more worrying that of the 32 antibacterials that target the WHO priority pathogens, only 6 of these agents fulfill at least 1 of the innovation criteria as defined by the WHO expert group (absence of known cross resistance, new class, new target; new mode of action). Only two of these are active against the critical MDR Gram-negative bacteria: two boronate β-lactamase inhibitors (taniborbactam + cefepime and VNRX-7145 + ceftibuten) in phases 3 and 1, respectively, targeting CRE. The additional four innovative treatments constitute two new topoisomerase inhibitors (zoliflodacin and gepotidacin) in phase 3, a new FabI inhibitor (afabicin) in phase 2, and a novel FtsZ inhibitor (TXA709) in phase 1.

Most of the agents in development are in fact derivatives of existing classes. Forty percent of the pipeline targeting WHO priority pathogens consists of additional β-lactam and β-lactamase inhibitor combinations, with a major gap in activity against metallo-β-lactamase (MBL) producers. From the perspective of a drug developer, the advantage of following this strategy is that they can rely on a well-characterized, validated clinical pathway to market. Very often first in class also does not equal best in class, meaning that optimized derivatives can have better safety or efficacy profiles. On the downside, some level of cross-resistance and fast adaptation of bacterial populations can be expected. The state of the pipeline reflects the fact that finding novel compounds with new binding sites and new modes of action is very difficult and risky. Finding compounds with more than one binding site to avoid single-step resistance, which are able to penetrate the outer layer of Gram-negative cell walls and avoid being pumped out immediately by efflux pumps, is scientifically very challenging on top of the fact that these agents need to kill bacteria without being (too) toxic at the required concentration.

In light of the average development time from phase 1 until approval of approximately 7 years and the average progression rates, the current clinical pipeline could lead to approximately 11 new antibiotic approvals in the next 5 years, but the majority of those would be agents of existing classes. However, the current economic environment for antibacterial research and development unfortunately makes it likely that fewer agents than that will make it to market approval. Overall, the clinical pipeline remains insufficient to tackle the challenge of increasing emergence and spread of antibiotic resistance. It fails to address the problem of extensively or pan-drug-resistant Gram-negative bacteria, in particular, carbapenem-resistant A. baumannii and P. aeruginosa.

Since July 1, 2017, eight new antibiotics that have been approved by the FDA and EMA (delafloxacin, vaborbactam + meropenem, eravacycline, omadacycline, relebactam + imipenem/cilastatin, lefamulin, plazomicin, and pretomanid). Of these, only two, vaborbactam + Meropenem and lefamulin, represent a new chemical class. All the others are derivatives of known classes such as the two tetracyclines eravacycline and omadacycline.

The common challenge is that their clinical advantages over existing treatment regimens are not clearly established and not underpinned by clinical trial outcomes when noninferiority trials show only that new treatments equal the standard of care. How can you convince clinicians of the potential value of these drugs in this situation if, in addition, the new products are more expensive than existing (generic) antibiotics? It is evident that in the current market environment most of them will struggle to find a place in the treatment landscape and in treatment guidelines and formularies. Consequently, small companies will find it difficult to survive economically. The bankruptcy of Achaogen, the company that marketed plazomicin, and the recent Chapter 11 bankruptcy filing of Melinta, which had four antibiotics on the market including delafloxacin and meropenem-vaborbactam, are telling examples.

It is clear that more public engagement is needed and that it cannot be sustainable if reimbursement schemes and payers do not remunerate new, more effective, and innovative treatments that can overcome existing resistance mechanisms. It is, however, too easy to just ask for more money and higher prices; resources also have to be used more efficiently. Existing resources flowing into research and development and any new pull mechanism should focus only on those agents in the pipeline that are innovative and/or add significant clinical value and consequently have a chance to survive on the market. The major pharmaceutical companies also need to reengage and stop freeriding on public investment. It is encouraging that the industry, governments, and other concerned stakeholders are currently discussing new ideas, and it is hoped that we will see major new contributions over the coming years that allow new antibacterial treatments that have significant added clinical value to survive on the market.

In order to support these efforts, the AMR division of the WHO will continue to provide guidance and endeavor to coordinate efforts that tackle the current R&D gap. (9) WHO will maintain the global priority pathogen list of antibiotic-resistant bacteria to guide research and development investments and will continue to track the antibacterial preclinical and clinical development pipeline against priority pathogens and work closely with the Global Antimicrobial Resistance Research and Development Hub. WHO will also publish target product profiles that can assist companies and foundations in developing treatments that are adding significant public health value. WHO will continue to support GARDP as an independent global research and development entity as well as other existing and future research and development initiatives to ensure that these efforts focus on public health needs.

In addition, the AMR division works closely with governments to support the implementation of national action plans on antimicrobial resistance. This includes strengthening multisectoral governance, advocacy and awareness initiatives, and strengthening national surveillance systems. WHO also supports national and hospital efforts to monitor the consumption and use of existing antibiotics and provide guidance on the implementation of antimicrobial stewardship programs linked to infection prevention and control measures. Only through a holistic One Health approach can antimicrobial resistance be contained.

Author Information

Click to copy section linkSection link copied!
  • Corresponding Author
    • Peter Beyer - AMR Division, World Health Organization, Geneva 1202, Switzerland;  Email: [email protected]
  • Author
  • Notes
    The authors declare no competing financial interest.

Acknowledgments

Click to copy section linkSection link copied!

This contribution has been prepared strictly in a personal capacity and reflects the view of the authors. The views expressed must not be attributed to the WHO, its Secretariat, or its Member States. The reports mentioned were funded by the Government of Austria and the Global Antibiotic Research and Development Partnership (GARDP). We thank the WHO expert advisory group for their contributions to the report WHO 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline: Ursula Theuretzbacher, Mark Butler, Lloyd Czaplewski, Stephan Harbarth, Jennie Hood, François Franceschi, Roman Kozlov, Christian Lienhardt, Norio Ohmagari, Mical Paul, John H. Rex, Lynn Silver, and Guy Thwaites. We also thank Richard Alm for his contributions to the WHO report Antibacterial Agents in Preclinical Development: An Open Access Database.

References

Click to copy section linkSection link copied!

This article references 9 other publications.

  1. 1
    No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Secretary-General of the United Nations; World Health Organization: Geneva, 2019.
    Google Scholar
    There is no corresponding record for this reference.
  2. 2
    Declaration G20 Meeting of Health Ministers Mar del Plata: G20; 2018 (http://www.g20.utoronto.ca/2018/2018-10-04-health.pdf, accessed Jan 10, 2020).
    Google Scholar
    There is no corresponding record for this reference.
  3. 3
    G20 Leaders’ Declaration: Shaping an Interconnected World Hamburg: G20; 2017 (https://ec.europa.eu/commission/presscorner/detail/en/STATEMENT_17_1960, accessed Jan 10, 2020).
    Google Scholar
    There is no corresponding record for this reference.
  4. 4
    Antibacterial Agents in Preclinical Development: An Open Access Database; World Health Organization: Geneva, 2019.
    Google Scholar
    There is no corresponding record for this reference.
  5. 5
    Theuretzbacher, U., Outterson, K. K., Engel, A., and Karlén, A. (2020) The global preclinical antibacterial pipeline. Nat. Rev. Microbiol. 18, 275– 285,  DOI: 10.1038/s41579-019-0288-0
    Google Scholar
    5
    The global preclinical antibacterial pipeline
    Theuretzbacher Ursula; Outterson Kevin; Outterson Kevin; Engel Aleks; Karlen Anders
    Nature reviews. Microbiology (2020), 18 (5), 275-285 ISSN:.
    Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable. This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not adequately addressed yet, especially development pathways to show clinical impact of non-traditional approaches. The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfgvFyksA%253D%253D&md5=23ae61239f8792a0fa6ed5b48ae11dcf
  6. 6
    2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline; World Health Organization: Geneva, 2019.
    Google Scholar
    There is no corresponding record for this reference.
  7. 7
    AMR Industry Alliance 2020 Progress Report; AMR Industry Alliance: Geneva, 2020.
    Google Scholar
    There is no corresponding record for this reference.
  8. 8
    The Biopharmaceutical Pipeline: Innovative Therapies in Clincial Development; Analysis Group: Boston, 2017.
    Google Scholar
    There is no corresponding record for this reference.
  9. 9
    Beyer, P., Moorthy, V., Paulin, S., Hill, S. R., Sprenger, M., Garner, S., Simão, M., Guerra, R., Magrini, N., and Swaminathan, S. (2018) The drugs don’t work: WHO’s role in advancing new antibiotics. Lancet 392, 264– 6,  DOI: 10.1016/S0140-6736(18)31570-8
    Google Scholar
    9
    The drugs don't work: WHO's role in advancing new antibiotics
    Beyer Peter; Paulin Sarah; Hill Suzanne R; Garner Sarah; Magrini Nicola; Moorthy Vasee; Sprenger Marc; Guerra Ranieri; Simao Mariangela; Swaminathan Soumya
    Lancet (London, England) (2018), 392 (10144), 264-266 ISSN:.
    There is no expanded citation for this reference.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7jvVWhtw%253D%253D&md5=c3d0df204b9f50bfbf8a1fa9f03b02ac

Cited By

Click to copy section linkSection link copied!

This article is cited by 51 publications.

  1. Adam M. Varney, Kirsty L. Smitten, Hannah M. Southam, Simon D. Fairbanks, Craig C. Robertson, Jim A. Thomas, Samantha McLean. In Vitro and In Vivo Studies on a Mononuclear Ruthenium Complex Reveals It is a Highly Effective, Fast-Acting, Broad-Spectrum Antimicrobial in Physiologically Relevant Conditions. ACS Infectious Diseases 2024, 10 (9) , 3346-3357. https://doi.org/10.1021/acsinfecdis.4c00447
  2. François Moreau, Dmytro Atamanyuk, Markus Blaukopf, Marek Barath, Mihály Herczeg, Nuno M. Xavier, Jérôme Monbrun, Etienne Airiau, Vivien Henryon, Frédéric Leroy, Stéphanie Floquet, Damien Bonnard, Robert Szabla, Chris Brown, Murray S. Junop, Paul Kosma, Vincent Gerusz. Potentiating Activity of GmhA Inhibitors on Gram-Negative Bacteria. Journal of Medicinal Chemistry 2024, 67 (8) , 6610-6623. https://doi.org/10.1021/acs.jmedchem.4c00037
  3. Seong-Heun Kim, Charlotte K. Hind, Guilherme F. S. Fernandes, Jingyue Wu, Dorothy Semenya, Melanie Clifford, Caleb Marsh, Silvia Anselmi, A. James Mason, Kenneth D. Bruce, J. Mark Sutton, Daniele Castagnolo. Development of Novel Membrane Disrupting Lipoguanidine Compounds Sensitizing Gram-Negative Bacteria to Antibiotics. ACS Medicinal Chemistry Letters 2024, 15 (2) , 239-249. https://doi.org/10.1021/acsmedchemlett.3c00460
  4. Ana L. Santos, Dongdong Liu, Alexis van Venrooy, Jacob L. Beckham, Antonio Oliver, George P. Tegos, James M. Tour. Nonlethal Molecular Nanomachines Potentiate Antibiotic Activity Against Gram-Negative Bacteria by Increasing Cell Permeability and Attenuating Efflux. ACS Nano 2024, 18 (4) , 3023-3042. https://doi.org/10.1021/acsnano.3c08041
  5. Julia McCain, Sol R. Martínez, Florencia Fungo, Aya Sakaya, Gonzalo Cosa. Two-Pronged Dormant Photosensitizer-Antibiotic Bacterial Inactivation: Mechanism, Dosage, and Cellular Evolution Visualized at the Single-Cell Level. Journal of the American Chemical Society 2023, 145 (51) , 28124-28136. https://doi.org/10.1021/jacs.3c10034
  6. Naila Zaman, Syed Sikander Azam. Discrete Dynamics of Warhead Modulation on Covalent Inhibition of Oxyr: A QM/MM Study. The Journal of Physical Chemistry B 2023, 127 (27) , 5993-6005. https://doi.org/10.1021/acs.jpcb.2c07376
  7. Steven L. Regen. Membrane-Disrupting Molecules as Therapeutic Agents: A Cautionary Note. JACS Au 2021, 1 (1) , 3-7. https://doi.org/10.1021/jacsau.0c00037
  8. Ravallika Aluri, Aishwarya Natarajan, Tarun Patel, Darakhshan Begum, Jyothi Kumari, Dharmarajan Sriram, Balaram Ghosh, Krishnan Rangan. Synthesis, characterisation, single crystal structure and evaluation of a redox innocent carbazate functionalized phenanthroline for antimycobacterial and anticancer activity. Journal of Molecular Structure 2025, 1323 , 140729. https://doi.org/10.1016/j.molstruc.2024.140729
  9. Liang Luo, Qing Li, Chen Xing, Chenglong Li, Yantong Pan, He Sun, Xuezhi Yu, Kai Wen, Jianzhong Shen, Zhanhui Wang. Antibody-based therapy: An alternative for antimicrobial treatment in the post-antibiotic era. Microbiological Research 2025, 290 , 127974. https://doi.org/10.1016/j.micres.2024.127974
  10. Zhiteng Luo, Jingtian Su, Siting Luo, Yingchen Ju, Bingyi Chen, Qiong Gu, Huihao Zhou. Structure-guided inhibitor design targeting CntL provides the first chemical validation of the staphylopine metallophore system in bacterial metal acquisition. European Journal of Medicinal Chemistry 2024, 280 , 116991. https://doi.org/10.1016/j.ejmech.2024.116991
  11. Hana Brzobohatá, Milica Dugić, Viktor Mojr, Nitjawan Sahatsapan, Ivana Kóšiová, Tomáš Křížek, Tereza Dolejšová, Petra Lišková, Lukasz Cwiklik, Dominik Rejman, Radovan Fišer, Gabriela Mikušová. LEGO-LPPO membrane activity is enhanced by presence of phosphatidylethanolamine but hindered by outer membrane. 2024https://doi.org/10.21203/rs.3.rs-5103062/v1
  12. Jianbang Wu, Changmao Wang, Rong Zhang, Pengfei Du, Yaqin Wang, Ping Wu, Xinyan Chen, Yunzhe Huang, Yuanwei Jia, Jie Shen. SIL‐IS LC–ESI–MS/MS method for simultaneous quick detection of amoxicillin and clavulanic acid in human plasma: Development, validation and its application to a pharmacokinetics study. Biomedical Chromatography 2024, 38 (11) https://doi.org/10.1002/bmc.5964
  13. Peri B. Moulding, Omar M. El-Halfawy. Chemical-mediated virulence: the effects of host chemicals on microbial virulence and potential new antivirulence strategies. Canadian Journal of Microbiology 2024, 70 (10) , 405-425. https://doi.org/10.1139/cjm-2024-0017
  14. Ricardo S. Moura, João Pedro R. Afonso, Diego A. C. P. G. Mello, Renata Kelly Palma, Iransé Oliveira-Silva, Rodrigo F. Oliveira, Deise A. A. P. Oliveira, Dante B. Santos, Carlos Hassel M. Silva, Orlando A. Guedes, Giuseppe Insalaco, Luís V. F. Oliveira. Hydrogels Associated with Photodynamic Therapy Have Antimicrobial Effect against Staphylococcus aureus: A Systematic Review. Gels 2024, 10 (10) , 635. https://doi.org/10.3390/gels10100635
  15. Tarosha Salpadoru, Kevin E. Pinks, Jacob A. Lieberman, Kaitlyn Cotton, Karen L. Wozniak, Nikolay Gerasimchuk, Marianna A. Patrauchan, . Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens. Microbiology Spectrum 2024, 12 (6) https://doi.org/10.1128/spectrum.04234-23
  16. Julia Werner, Florian Umstätter, Tobias Hertlein, Eric Mühlberg, Barbro Beijer, Sabrina Wohlfart, Stefan Zimmermann, Uwe Haberkorn, Knut Ohlsen, Gert Fricker, Walter Mier, Philipp Uhl. Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier. Advanced Healthcare Materials 2024, 13 (14) https://doi.org/10.1002/adhm.202303654
  17. Pragya Tiwari, Shreya Thakkar, Laurent Dufossé. Antimicrobials from endophytes as novel therapeutics to counter drug-resistant pathogens. Critical Reviews in Biotechnology 2024, 2022 , 1-27. https://doi.org/10.1080/07388551.2024.2342979
  18. Juan Carvajal-Garcia, Harrison Bracey, Anna E Johnson, Angel J Hernandez Viera, Martin Egli, Esra N Simsek, Emily A Jaremba, Kwangho Kim, Houra Merrikh. A small molecule that inhibits the evolution of antibiotic resistance. NAR Molecular Medicine 2024, 1 (1) https://doi.org/10.1093/narmme/ugae001
  19. Vera Vollenweider, Karoline Rehm, Clara Chepkirui, Manuela Pérez-Berlanga, Magdalini Polymenidou, Jörn Piel, Laurent Bigler, Rolf Kümmerli. Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens. 2024https://doi.org/10.7554/eLife.92493.1
  20. Vera Vollenweider, Karoline Rehm, Clara Chepkirui, Manuela Pérez-Berlanga, Magdalini Polymenidou, Jörn Piel, Laurent Bigler, Rolf Kümmerli. Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens. 2024https://doi.org/10.7554/eLife.92493
  21. Mary C. Okorie, Ayuni Yussof, Tinchun Chu, Sergiu M. Gorun. Broad photodynamic antibacterial activity of a functionalized, highly fluorinated sensitizer. Journal of Porphyrins and Phthalocyanines 2024, 28 (01) , 11-22. https://doi.org/10.1142/S1088424623501237
  22. Zixiu Wang, Yan Huang, Dandan Deng, Shan Li, Yimei Yu, Yifei Ye, Yi Chen, Jian Lei. Facile synthesis and antifungal evaluation of hypervalent organoantimony( iii ) and organobismuth( iii ) thioates with tridentate C,N,C-coordinating ligands. Organic & Biomolecular Chemistry 2024, 6 https://doi.org/10.1039/D4OB00702F
  23. Meenakshi Venkatesan, Michael Fruci, Lou Ann Verellen, Tatiana Skarina, Nathalie Mesa, Robert Flick, Chester Pham, Radhakrishnan Mahadevan, Peter J. Stogios, Alexei Savchenko. Molecular mechanism of plasmid-borne resistance to sulfonamide antibiotics. Nature Communications 2023, 14 (1) https://doi.org/10.1038/s41467-023-39778-7
  24. Edward Ntim Gasu, John Kenneth Mensah, Lawrence Sheringham Borquaye. Computer-aided design of proline-rich antimicrobial peptides based on the chemophysical properties of a peptide isolated from Olivancillaria hiatula. Journal of Biomolecular Structure and Dynamics 2023, 41 (17) , 8254-8275. https://doi.org/10.1080/07391102.2022.2131626
  25. Pei-Yao Xu, Ranjith Kumar Kankala, Shi-Bin Wang, Ai-Zheng Chen. Sonodynamic therapy-based nanoplatforms for combating bacterial infections. Ultrasonics Sonochemistry 2023, 100 , 106617. https://doi.org/10.1016/j.ultsonch.2023.106617
  26. Kinga Skrzyniarz, Dorota Kuc-Ciepluch, Magdalena Lasak, Michał Arabski, Javier Sanchez-Nieves, Karol Ciepluch. Dendritic systems for bacterial outer membrane disruption as a method of overcoming bacterial multidrug resistance. Biomaterials Science 2023, 11 (19) , 6421-6435. https://doi.org/10.1039/D3BM01255G
  27. Diana Persia, Francesca Mangiavacchi, Maria Carla Marcotullio, Ornelio Rosati. Cannabinoids as multifaceted compounds. Phytochemistry 2023, 212 , 113718. https://doi.org/10.1016/j.phytochem.2023.113718
  28. Franziska Fries, Andreas Kany, Sari Rasheed, Anna Hirsch, Rolf Müller, Jennifer Herrmann. Impact of Drug Administration Routes on the In Vivo Efficacy of the Natural Product Sorangicin A Using a Staphylococcus aureus Infection Model in Zebrafish Embryos. International Journal of Molecular Sciences 2023, 24 (16) , 12791. https://doi.org/10.3390/ijms241612791
  29. Antje Labes. Marine Resources Offer New Compounds and Strategies for the Treatment of Skin and Soft Tissue Infections. Marine Drugs 2023, 21 (7) , 387. https://doi.org/10.3390/md21070387
  30. Zhenhua Wu, Xiaoli Zhu, Anjin Hong, Guanghui He, Zheng Wang, Qingyan Xu, Zhiyu Hu, Xiaobing Wu, Yuezhou Wang, Qiufang Chen, Xilin Zhao, Li Li, Xianming Deng. Discovery of urea-based pleuromutilin derivatives as potent gram-positive antibacterial agents. Bioorganic Chemistry 2023, 136 , 106547. https://doi.org/10.1016/j.bioorg.2023.106547
  31. Laura Cresti, Giovanni Cappello, Silvia Vailati, Elsa Melloni, Jlenia Brunetti, Chiara Falciani, Luisa Bracci, Alessandro Pini. In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation. International Journal of Molecular Sciences 2023, 24 (9) , 7967. https://doi.org/10.3390/ijms24097967
  32. Lisa Myrseth Hemmingsen, Barbara Giordani, Marianne H. Paulsen, Željka Vanić, Gøril Eide Flaten, Beatrice Vitali, Purusotam Basnet, Annette Bayer, Morten B. Strøm, Nataša Škalko-Basnet. Tailored anti-biofilm activity – Liposomal delivery for mimic of small antimicrobial peptide. Biomaterials Advances 2023, 145 , 213238. https://doi.org/10.1016/j.bioadv.2022.213238
  33. Jack Adderley, Georges E Grau. Host-directed therapies for malaria: possible applications and lessons from other indications. Current Opinion in Microbiology 2023, 71 , 102228. https://doi.org/10.1016/j.mib.2022.102228
  34. Piotr Neumann, Patrick Kloskowski, Ralf Ficner. Computer-aided design of a cyclic di-AMP synthesizing enzyme CdaA inhibitor. microLife 2023, 4 https://doi.org/10.1093/femsml/uqad021
  35. Atanas Pipite, Peter J. Lockhart, Patricia A. McLenachan, Ketan Christi, Dinesh Kumar, Surendra Prasad, Ramesh Subramani. Isolation, antibacterial screening, and identification of bioactive cave dwelling bacteria in Fiji. Frontiers in Microbiology 2022, 13 https://doi.org/10.3389/fmicb.2022.1012867
  36. Valentina Vignali, Philip A. Hines, Ana Glória Cruz, Barbara Ziętek, Ralf Herold. Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations. Frontiers in Medicine 2022, 9 https://doi.org/10.3389/fmed.2022.1064003
  37. David Klarić, Marijana Pocrnić, Dražen Lež, Saša Polović, Darko Kontrec, Ivan Kosalec, Ana Budimir, Nives Galić. Search for new antimicrobials: spectroscopic, spectrometric, and in vitro antimicrobial activity investigation of Ga(III) and Fe(III) complexes with aroylhydrazones. JBIC Journal of Biological Inorganic Chemistry 2022, 27 (8) , 715-729. https://doi.org/10.1007/s00775-022-01967-y
  38. K. Rox. Influence of tramadol on bacterial burden in the standard neutropenic thigh infection model. Scientific Reports 2022, 12 (1) https://doi.org/10.1038/s41598-022-24111-x
  39. Huayao Chen, Hongkai Deng, Ximing Zhong, Hongjun Zhou, Jinghui Zhan, Xinhua Zhou. Highly dispersed amorphous ZnO on a petal-like porous silica-clay composite with enhanced antimicrobial properties. Colloids and Surfaces B: Biointerfaces 2022, 220 , 112978. https://doi.org/10.1016/j.colsurfb.2022.112978
  40. Chunying Liu, Shuangrong Ruan, Ying He, Xuejing Li, Yuefei Zhu, Honglan Wang, Hanwei Huang, Zhiqing Pang. Broad-spectrum and powerful neutralization of bacterial toxins by erythroliposomes with the help of macrophage uptake and degradation. Acta Pharmaceutica Sinica B 2022, 12 (11) , 4235-4248. https://doi.org/10.1016/j.apsb.2022.03.015
  41. Diego Navarro-Barreda, Rosa de Llanos, Juan F. Miravet, Francisco Galindo. Photodynamic inactivation of Staphylococcus aureus in the presence of aggregation-prone photosensitizers based on BODIPY used at submicromolar concentrations. Journal of Photochemistry and Photobiology B: Biology 2022, 235 , 112543. https://doi.org/10.1016/j.jphotobiol.2022.112543
  42. Ana M. López-Fernández, Evelina E. Moisescu, Rosa de Llanos, Francisco Galindo. Development of a Polymeric Film Entrapping Rose Bengal and Iodide Anion for the Light-Induced Generation and Release of Bactericidal Hydrogen Peroxide. International Journal of Molecular Sciences 2022, 23 (17) , 10162. https://doi.org/10.3390/ijms231710162
  43. Mohmmad Imran, Mohammad Naiyaz Ahmad, Arunava Dasgupta, Preeti Rana, Nanduri Srinivas, Sidharth Chopra. Novel Approaches for the Treatment of Infections Due to Multidrug-Resistant Bacterial Pathogens. Future Medicinal Chemistry 2022, 14 (15) , 1133-1148. https://doi.org/10.4155/fmc-2022-0029
  44. Alpesh N. Amin, E. Patchen Dellinger, Glenn Harnett, Bryan D. Kraft, Kerry L. LaPlante, Frank LoVecchio, James A. McKinnell, Glenn Tillotson, Salisia Valentine. It’s about the patients: Practical antibiotic stewardship in outpatient settings in the United States. Frontiers in Medicine 2022, 9 https://doi.org/10.3389/fmed.2022.901980
  45. Zhe Wang, Xingyun Liu, Yanwen Duan, Yong Huang. Infection microenvironment-related antibacterial nanotherapeutic strategies. Biomaterials 2022, 280 , 121249. https://doi.org/10.1016/j.biomaterials.2021.121249
  46. Lieby Zborovsky, Leonardo Kleebauer, Maria Seidel, Arseni Kostenko, Leonard von Eckardstein, Frank Otto Gombert, John Weston, Roderich D. Süssmuth. Improvement of the antimicrobial potency, pharmacokinetic and pharmacodynamic properties of albicidin by incorporation of nitrogen atoms. Chemical Science 2021, 12 (43) , 14606-14617. https://doi.org/10.1039/D1SC04019G
  47. Mukunda R. Patekar, Vijay J. Medhane, Ghanshyam J. Jadhav, Mayur J. Thakare, Dattatray G. Deshmukh. Synthesis of (s)‐1‐{3‐[4‐(4‐benzo[d]isothiazol‐3‐yl‐piperazin‐1‐yl)‐3‐fluoro‐phenyl]‐2‐oxo‐oxazolidin‐5‐ylmetyl}‐3‐substituted‐urea derivatives as antibacterial agents. Journal of Heterocyclic Chemistry 2021, 58 (11) , 2152-2162. https://doi.org/10.1002/jhet.4342
  48. Marcus Miethke, Marco Pieroni, Tilmann Weber, Mark Brönstrup, Peter Hammann, Ludovic Halby, Paola B. Arimondo, Philippe Glaser, Bertrand Aigle, Helge B. Bode, Rui Moreira, Yanyan Li, Andriy Luzhetskyy, Marnix H. Medema, Jean-Luc Pernodet, Marc Stadler, José Rubén Tormo, Olga Genilloud, Andrew W. Truman, Kira J. Weissman, Eriko Takano, Stefano Sabatini, Evi Stegmann, Heike Brötz-Oesterhelt, Wolfgang Wohlleben, Myriam Seemann, Martin Empting, Anna K. H. Hirsch, Brigitta Loretz, Claus-Michael Lehr, Alexander Titz, Jennifer Herrmann, Timo Jaeger, Silke Alt, Thomas Hesterkamp, Mathias Winterhalter, Andrea Schiefer, Kenneth Pfarr, Achim Hoerauf, Heather Graz, Michael Graz, Mika Lindvall, Savithri Ramurthy, Anders Karlén, Maarten van Dongen, Hrvoje Petkovic, Andreas Keller, Frédéric Peyrane, Stefano Donadio, Laurent Fraisse, Laura J. V. Piddock, Ian H. Gilbert, Heinz E. Moser, Rolf Müller. Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry 2021, 5 (10) , 726-749. https://doi.org/10.1038/s41570-021-00313-1
  49. Ali Salama, Ammar Almaaytah, Rula M. Darwish. The Design of Alapropoginine, a Novel Conjugated Ultrashort Antimicrobial Peptide with Potent Synergistic Antimicrobial Activity in Combination with Conventional Antibiotics. Antibiotics 2021, 10 (6) , 712. https://doi.org/10.3390/antibiotics10060712
  50. Dilip Roy, Amol Kulkarni, Manu Chaudhary, Saransh Chaudhary, Anurag Payasi, Anmol Aggarwal. Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats. Antibiotics 2021, 10 (4) , 359. https://doi.org/10.3390/antibiotics10040359
  51. Steven L. Regen. Improving the Cellular Selectivity of a Membrane-Disrupting Antimicrobial Agent by Monomer Control and by Taming. Molecules 2021, 26 (2) , 374. https://doi.org/10.3390/molecules26020374
  52. Vivian Garzón, Rosa-Helena Bustos, Daniel G. Pinacho. Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring. Journal of Personalized Medicine 2020, 10 (4) , 147. https://doi.org/10.3390/jpm10040147
  53. Anna K. Krome, Tim Becker, Stefan Kehraus, Andrea Schiefer, Christian Steinebach, Tilman Aden, Stefan J. Frohberger, Álvaro López Mármol, Dnyaneshwar Kapote, Rolf Jansen, Lillibeth Chaverra-Muñoz, Marc P. Hübner, Kenneth Pfarr, Thomas Hesterkamp, Marc Stadler, Michael Gütschow, Gabriele M. König, Achim Hoerauf, Karl G. Wagner. Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A. Pharmaceutics 2020, 12 (11) , 1105. https://doi.org/10.3390/pharmaceutics12111105
  54. Cheng Chen, Kewu Yang. Ruthenium complexes as prospective inhibitors of metallo-β-lactamases to reverse carbapenem resistance. Dalton Transactions 2020, 49 (40) , 14099-14105. https://doi.org/10.1039/D0DT02430A
Download PDF
Go to ACS Infectious Diseases
Get e-Alerts
Get e-Alerts

ACS Infectious Diseases

Cite this: ACS Infect. Dis. 2020, 6, 6, 1289–1291
Click to copy citationCitation copied!
https://doi.org/10.1021/acsinfecdis.0c00044
Published June 12, 2020

Copyright © 2020 American Chemical Society. This publication is available under these Terms of Use.

Request reuse permissions

Article Views

6117

Altmetric

-

Citations

51
Learn about these metrics

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.

Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.

The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated.

  • Scheme 1

    Scheme 1. Clinical Antibacterial Pipeline
    High Resolution Image
    Download MS PowerPoint Slide

  • References

    This article references 9 other publications.

    1. 1
      No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Secretary-General of the United Nations; World Health Organization: Geneva, 2019.
      There is no corresponding record for this reference.
    2. 2
      Declaration G20 Meeting of Health Ministers Mar del Plata: G20; 2018 (http://www.g20.utoronto.ca/2018/2018-10-04-health.pdf, accessed Jan 10, 2020).
      There is no corresponding record for this reference.
    3. 3
      G20 Leaders’ Declaration: Shaping an Interconnected World Hamburg: G20; 2017 (https://ec.europa.eu/commission/presscorner/detail/en/STATEMENT_17_1960, accessed Jan 10, 2020).
      There is no corresponding record for this reference.
    4. 4
      Antibacterial Agents in Preclinical Development: An Open Access Database; World Health Organization: Geneva, 2019.
      There is no corresponding record for this reference.
    5. 5
      Theuretzbacher, U., Outterson, K. K., Engel, A., and Karlén, A. (2020) The global preclinical antibacterial pipeline. Nat. Rev. Microbiol. 18, 275– 285,  DOI: 10.1038/s41579-019-0288-0
      5
      The global preclinical antibacterial pipeline
      Theuretzbacher Ursula; Outterson Kevin; Outterson Kevin; Engel Aleks; Karlen Anders
      Nature reviews. Microbiology (2020), 18 (5), 275-285 ISSN:.
      Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable. This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not adequately addressed yet, especially development pathways to show clinical impact of non-traditional approaches. The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfgvFyksA%253D%253D&md5=23ae61239f8792a0fa6ed5b48ae11dcf
    6. 6
      2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline; World Health Organization: Geneva, 2019.
      There is no corresponding record for this reference.
    7. 7
      AMR Industry Alliance 2020 Progress Report; AMR Industry Alliance: Geneva, 2020.
      There is no corresponding record for this reference.
    8. 8
      The Biopharmaceutical Pipeline: Innovative Therapies in Clincial Development; Analysis Group: Boston, 2017.
      There is no corresponding record for this reference.
    9. 9
      Beyer, P., Moorthy, V., Paulin, S., Hill, S. R., Sprenger, M., Garner, S., Simão, M., Guerra, R., Magrini, N., and Swaminathan, S. (2018) The drugs don’t work: WHO’s role in advancing new antibiotics. Lancet 392, 264– 6,  DOI: 10.1016/S0140-6736(18)31570-8
      9
      The drugs don't work: WHO's role in advancing new antibiotics
      Beyer Peter; Paulin Sarah; Hill Suzanne R; Garner Sarah; Magrini Nicola; Moorthy Vasee; Sprenger Marc; Guerra Ranieri; Simao Mariangela; Swaminathan Soumya
      Lancet (London, England) (2018), 392 (10144), 264-266 ISSN:.
      There is no expanded citation for this reference.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7jvVWhtw%253D%253D&md5=c3d0df204b9f50bfbf8a1fa9f03b02ac